Oncimmune Holdings full year results and conference call

DirectorsTalk Interviews

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, states that it will be announcing its full year results for the year ended 31st May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at [email protected] or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

• The online presentation will be open to all existing shareholders and potential new investors.

• Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

• Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Oncimmune Holdings will automatically receive an invitation to the presentation.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Grid shift strengthens the case for flexible power

Britain’s move away from fossil fuel generation is increasing the value of flexible power assets as demand from AI, electrification and grid balancing grows.

Switch Metals moves towards drilling as lithium market interest returns

Switch Metals prepares to drill lithium targets at Issia while advancing tantalum resource work in a recovering lithium market.

Tile Africa expands kitchen appeal with Abode water filtration range

Tile Africa’s Abode kitchen range gives customers a practical filtered-water upgrade while strengthening the retailer’s broader kitchen category offer.

IP Group portfolio company Istesso begins Phase 2 trial of leramistat

Istesso has started dosing in a Phase 2 trial of leramistat in rheumatoid arthritis-related sarcopenia, evaluating its effects on muscle quality, repair and function.

Pennon Group reports improved 2026 performance and return to profit

Pennon reported a return to profitability in 2026, with revenue rising to £1.29bn, underlying EBITDA up to £519.2m and statutory profit before tax of £114.4m, alongside progress on pollution reduction and storm overflow performance.

Cizzle Biotechnology’s CIZ1B early lung cancer test gains CLIA accreditation in the US

Cizzle Biotechnology’s CIZ1B biomarker blood test has received CLIA accreditation at OmniHealth Diagnostics in Texas, enabling U.S. healthcare providers to order the early-stage lung cancer test.

    Search